Figure 1 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Year: 2026
Type: other
Abstract: Characterization of ErlR and AfaR HNSCC cell models. A and B, Dose response curves for (A) Fadu and (B) Cal27 parental, ErlR, or AfaR cell lines treated with the indicated dose range of afatinib or erlotinib for 72 hours. C, Representative Western blot images for active RTKs EGFR, MET, and HER2. D, Quantification of Western blots shown in C, with values normalized to those in parental cell lines. Graphs display baseline activation relative to total levels of each protein, based on n = 3. Note that for some proteins analyzed (e.g., MET), there was a significant intensity difference between FaDu and Cal27 models. For these cases, multiple exposures were taken for the relevant data, and quantification was performed based on primary Western blot data within a linear signal range. E, GSEA comparing Fadu and Cal27 AfaR or ErlR vs. Fadu and Cal27 parental cells, as indicated. RNA-seq analysis shown is averaged from two biological replicates. F and G, Representative Western blot images (F) and quantification (G) for indicated biomarkers of epithelial identity or EMT, based on n = 3 biological repeats. Bar graphs display data normalized for each parental cell line. P values are based on one-way ANOVA followed by Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates. ES, enrichment score.
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7202360113
Cites:
Cited by:
Related to: